Table 1.
Characteristics of the trials and patients included in the meta-analysis.
| Author | Year | Region | Study Design | Phase | Arm | Treatment arms | Patients enrolled, n | Sample size | Sex | Median age, years | malignancy | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Women | Men | ||||||||||||
| Moroney et al. (14) | 2020 | USA | Single arm | Ib | 1 | A-B | 20 | 20 | 20 (100%) | 0 (0%) | 59 (37-80) | OC | |
| Morris et al. (15) | 2020 | USA | Single arm | II | 1 | A-B | 20 | 20 | – | – | 59 (43-80) | AC | |
| McGregor et al. (16) | 2020 | USA | Single arm | II | 1 | A-B | 60 | 60 | 13 (22%) | 47 (78%) | 61 (22–82) | RCC | |
| Lee et al. (9) | 2020 | USA, AUS, China, Japan, Korea, New Zealand, Taiwan | RCT | Ib | 2 | A-B Atezolizumab | 223 | 104 | 20 (19%) | 84 (81%) | 62 (23–82) | HCC | |
| Halperin et al. (12) | 2020 | USA | Single arm | II | 1 | A-B | 40 | 40 | – | – | – | NETs | |
| Friedman et al. (11) | 2020 | USA | Single arm | II | 1 | A-B | 11 | 11 | 11 (100%) | 0 (0%) | 48 (31–55) | CC | |
| Finn et al. (8) | 2020 | USA, AUS, Canada, China, Czechia, France, Germany, Hong Kong, Italy, Japan, Korea, Poland, Russia, Singapore, Spain, Taiwan, UK | RCT | III | 2 | A-B Sorafenib |
501 | 336 | 109 (18%) | 227 (82%) | 64 (56–71) | HCC | |
| Rini et al. (7) | 2019 | USA, AUS, Bosnia and Herzegovina, Brazil, Canada, Czechia, Denmark, France, Germany, Italy, Japan, Korea, Mexico, Poland, Russia, Singapore, Spain, Taiwan, Thailand, Turkey, UK | RCT | III | 2 | A-B Sunitinib |
915 | 454 | 137 (30%) | 317 (70%) | 62 (56–69) | RCC | |
| McDermott et al. (6) | 2018 | USA, Czechia, France, Germany, Italy, Poland, Romania, Spain, UK | RCT | II | 3 | A-B Atezolizumab Sunitinib |
305 | 101 | 27 (27%) | 74 (73%) | 62 (32-88) | RCC | |
| Wallin et al. (5) | 2016 | USA | Single arm | Ib | 1 | A-B | 11 | 10 | 3 (27%) | 8 (73%) | 59 (42-74) | RCC | |
RCT, randomized controlled trial; A-B, atezolizumab, and bevacizumab; -, not available; OC, ovarian cancer; AC, anal cancer; RCC, renal cancer carcinoma; HCC, hepatocellular carcinoma; NETs, neuroendocrine tumors; CV, cervical cancer.